AMY-101

Category	SARS-CoV
CAS	1427001-89-5
Description	C3 Complement Inhibitor AMY-101 is a compstatin-based inhibitor of human complement component C3. AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation.

Quotation Now

Product Information

Synonyms	Compstatin 40; Cp40
IUPAC Name	2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
Molecular Weight	1789.11
Molecular Formula	C83H117N23O18S2
Canonical SMILES	CCC(C)C(C(=O)NC1CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CN(C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)C(C)C)CC2=CN(C3=CC=CC=C32)C)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N(C)C(C(C)CC)C(=O)N)NC(=O)C(CC7=CC=C(C=C7)O)N
InChI	InChI=1S/C83H117N23O18S2/c1-11-43(5)68(103-72(114)53(84)30-46-23-25-50(107)26-24-46)80(122)100-61-39-125-126-40-62(82(124)106(10)69(70(86)112)44(6)12-2)101-73(115)55(21-17-29-90-83(87)88)94-76(118)58(33-49-36-89-41-92-49)96-71(113)45(7)93-65(109)38-105(9)81(123)60(31-47-35-91-54-20-15-13-18-51(47)54)99-77(119)59(34-66(110)111)97-74(116)56(27-28-64(85)108)95-75(117)57(98-79(121)67(42(3)4)102-78(61)120)32-48-37-104(8)63-22-16-14-19-52(48)63/h13-16,18-20,22-26,35-37,41-45,53,55-62,67-69,91,107H,11-12,17,21,27-34,38-40,84H2,1-10H3,(H2,85,108)(H2,86,112)(H,89,92)(H,93,109)(H,94,118)(H,95,117)(H,96,113)(H,97,116)(H,98,121)(H,99,119)(H,100,122)(H,101,115)(H,102,120)(H,103,114)(H,110,111)(H4,87,88,90)/t43-,44-,45-,53+,55-,56-,57-,58-,59-,60-,61-,62-,67-,68-,69-/m0/s1
InChIKey	MUSGYEMSJUFFHT-UWABRSFTSA-N
Purity	≥98%
Density	1.46±0.1 g/cm3(Predicted)
Solubility	Soluble in DMSO
Appearance	Solid Powder
Application	AMY-101 is a promising peptide API, also known as the C3 complement inhibitor AMY-101, with unique properties. The complement system is an important component of the immune response and plays a key role in the recognition and elimination of pathogens and the clearance of damaged cells and immune complexes. However, dysregulation of the complement system can lead to various diseases, including inflammatory diseases, autoimmune diseases, and ischemia-reperfusion injury. AMY-101 is a potent inhibitor of the C3 complement protein, a core component of the complement cascade. By targeting C3, AMY-101 effectively blocks activation of the complement system, thereby alleviating harmful immune responses and inflammation. This unique mechanism of action makes AMY-101 an attractive candidate for the treatment of diseases characterized by complement dysregulation. One important area in which AMY-101 exhibits significant potential is the management of inflammatory illnesses. The complement cascade and the immune system are overactive in inflammatory illnesses such lupus, rheumatoid arthritis, and inflammatory bowel disease. AMY-101 may lessen tissue damage, control inflammatory reactions, and soothe symptoms in people suffering from these conditions by blocking C3. The effectiveness of AMY-101 in animal models of inflammatory illnesses has been shown in several preclinical investigations, boosting expectations for its possible human application. Furthermore, AMY-101 exhibits significant promise in the domain of transplant medicine. Following organ donation, ischemia-reperfusion damage is a frequent complication that is partially mediated by the complement system. In organ transplantation models used in experiments, AMY-101 has demonstrated the ability to lessen tissue damage and increase graft life by blocking C3 activation. Currently, clinical trials are being conducted to assess AMY-101's safety and effectiveness in transplant patients; preliminary findings are positive. AMY-101 contains anti-inflammatory and anti-rejection qualities, but it may also be used to treat autoimmune disorders. The hallmark of autoimmune illnesses like autoimmune hemolytic anemia and systemic lupus erythematosus is the immune system attacking the body's own tissues by accident. AMY-101 may be able to treat these disorders by restoring immunological tolerance and reducing autoimmune reactions through complement system modulation. Promising preliminary research outcomes have opened the door for additional exploration of AMY-101's potential therapeutic uses in autoimmune disorders. Furthermore, AMY-101 may be very promising for the treatment of neurological conditions. Complement dysregulation may be involved in the pathophysiology of diseases like multiple sclerosis, Parkinson's disease, and Alzheimer's disease, according to new research. AMY-101 may be able to control neuroinflammation and neurodegeneration by targeting C3, offering a novel treatment strategy for these crippling conditions. With good results thus far, ongoing research are examining AMY-101's neuroprotective benefits in animal models of neurodegenerative illnesses.
Storage	Store at 2-8°C
Complexity	3770
Exact Mass	1787.83883632
In Vivo	AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis, and induce a long-lasting anti-inflammatory effect. AMY-101 does not cause irritation in healthy gingiva.
Target	Complement System; SARS-CoV
XLogP3-AA	-2.1